Schizophrenia Clinical Trial
Official title:
Clozapine for Cannabis Use Disorder in Schizophrenia
Many individuals with schizophrenia also suffer from marijuana addiction that worsens their
problems related to schizophrenia. Most of the medications prescribed for schizophrenia have
no effect on reducing marijuana use. Preliminary data suggests that clozapine, an atypical
antipsychotic, may limit marijuana use in people diagnosed with schizophrenia, but it is not
commonly used due to its side effects and is reserved for people who do not respond to other
antipsychotic medications.
In the proposed study, 132 individuals who are diagnosed with both schizophrenia and a
cannabis use disorder will be randomized to a 12-week treatment course with either clozapine
or risperidone (another commonly prescribed antipsychotic medication) to test the hypothesis
that patient treated with clozapine will have decreased cannabis use as compared to patients
treated with risperidone.
Should this study indicate that clozapine will lessen marijuana use in persons diagnosed with
schizophrenia more than risperidone, it will provide evidence needed to begin to shift
clinical practice toward its use in this population.
Cannabis use disorder (CUD), which is up to ten times more common in patients with
schizophrenia (SCZ) than in the general population, worsens the course of this severe
psychiatric disorder. Since SCZ occurs in 1% of the population, the co-occurrence of CUD in
13% to 42% of people with this disorder presents society with an important public health
problem. Unfortunately, most antipsychotics available for treatment of patients with SCZ do
not appear to limit their cannabis use. Moreover, the one antipsychotic that preliminary data
suggest may well limit cannabis use in these patients, clozapine (CLOZ), is not used for this
purpose; it is reserved for patients whose psychosis is treatment resistant.
The overarching idea behind this proposal, however, is that CLOZ's use is being unreasonably
restricted and should be made more widely available for patients with SCZ who have a
co-occurring CUD but whose psychosis is not necessarily treatment resistant. This notion is
supported by our preliminary clinical and animal data on the effects of CLOZ, as well as our
neurobiological model of the basis of cannabis use in patients with SCZ that provides a
pharmacologic rationale for this effect of CLOZ.
Even given all the arguments favoring the potential benefits of CLOZ in patients with SCZ and
CUD, however, its side effect profile will likely limit its use until a fully powered study
demonstrates its ability to decrease cannabis use in patients with SCZ. This proposal aims to
launch such a study. If, as we hypothesize, this study confirms and extends our previous
preliminary data of the effects of CLOZ in patients with SCZ and CUD, it will provide a
strong impetus to expand the use of CLOZ in this population.
In the proposed study, 132 patients who are comorbid for both SCZ and CUD will be randomized
to a 12-week treatment course with either CLOZ or risperidone (RISP) to test the hypothesis
that patients treated with CLOZ will have decreased cannabis use as compared to patients
treated with RISP. In addition, the study will determine whether patients treated with CLOZ
will have improvements in psychiatric symptoms, quality of life neuropsychological functions
as compared to those taking RISP. We will also explore whether patients taking CLOZ show
improved reward responsiveness as compared to those taking RISP. Finally, this study will
explore whether those patients with the val/val genotype at the Catechol-O-methyltransferase
(COMT) Val158Met locus are more likely to decrease cannabis use during CLOZ treatment than
are those without the val/val COMT genotype.
Should this study indicate that CLOZ will lessen cannabis use in patients with SCZ more than
RISP, it will provide evidence needed to begin to shift clinical practice toward its use in
these patients.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05039489 -
A Study on the Brain Mechanism of cTBS in Improving Medication-resistant Auditory Hallucinations in Schizophrenia
|
N/A | |
Completed |
NCT05111548 -
Brain Stimulation and Cognitive Training - Efficacy
|
N/A | |
Completed |
NCT05321602 -
Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder
|
Phase 1 | |
Completed |
NCT04503954 -
Efficacy of Chronic Disease Self-management Program in People With Schizophrenia
|
N/A | |
Completed |
NCT02831231 -
Pilot Study Comparing Effects of Xanomeline Alone to Xanomeline Plus Trospium
|
Phase 1 | |
Completed |
NCT05517460 -
The Efficacy of Auricular Acupressure on Improving Constipation Among Residents in Community Rehabilitation Center
|
N/A | |
Completed |
NCT03652974 -
Disturbance of Plasma Cytokine Parameters in Clozapine-Resistant Treatment-Refractory Schizophrenia (CTRS) and Their Association With Combination Therapy
|
Phase 4 | |
Recruiting |
NCT04012684 -
rTMS on Mismatch Negativity of Schizophrenia
|
N/A | |
Recruiting |
NCT04481217 -
Cognitive Factors Mediating the Relationship Between Childhood Trauma and Auditory Hallucinations in Schizophrenia
|
N/A | |
Completed |
NCT00212784 -
Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizophrenia or Schizoaffective Disorder (25517)(P05935)
|
Phase 3 | |
Completed |
NCT04092686 -
A Clinical Trial That Will Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia
|
Phase 3 | |
Completed |
NCT01914393 -
Pediatric Open-Label Extension Study
|
Phase 3 | |
Recruiting |
NCT03790345 -
Vitamin B6 and B12 in the Treatment of Movement Disorders Induced by Antipsychotics
|
Phase 2/Phase 3 | |
Recruiting |
NCT05956327 -
Insight Into Hippocampal Neuroplasticity in Schizophrenia by Investigating Molecular Pathways During Physical Training
|
N/A | |
Terminated |
NCT03261817 -
A Controlled Study With Remote Web-based Adapted Physical Activity (e-APA) in Psychotic Disorders
|
N/A | |
Terminated |
NCT03209778 -
Involuntary Memories Investigation in Schizophrenia
|
N/A | |
Completed |
NCT02905604 -
Magnetic Stimulation of the Brain in Schizophrenia or Depression
|
N/A | |
Recruiting |
NCT05542212 -
Intra-cortical Inhibition and Cognitive Deficits in Schizophrenia
|
N/A | |
Completed |
NCT04411979 -
Effects of 12 Weeks Walking on Cognitive Function in Schizophrenia
|
N/A | |
Terminated |
NCT03220438 -
TMS Enhancement of Visual Plasticity in Schizophrenia
|
N/A |